You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021446027
Dec 2021126012
Jan 2022174019
Feb 2022144021
Mar 2022298016
Apr 2022154021
May 2022110014
Jun 20228405
Jul 20226403
Aug 202212207
Sep 2022132016
Oct 20229008
Nov 20225808
Dec 20228006
Jan 20237809
Feb 20237404
Mar 20234001
Apr 20234404
May 20235204
Jun 20235003
Jul 202334011
Aug 20234603
Sep 20236603
Oct 20236407
Nov 2023104010
Dec 20234608
Jan 20244001
Feb 202444011
Mar 202410009
Apr 202478011
May 20245405
Jun 20246406
Jul 20248307
Aug 20246409
Sep 202496013
Total34030322